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Purpose: To assess the association between VKORC1 and CYP2C9 variants and the 
incidence of adverse drug reactions in warfarin-treated patients in a real-world setting.
Materials and Methods: This was a register-based cohort study (PreMed) linking data 
from Finnish biobanks, national health registries and patient records between 
January 1st 2007 and June 30th 2018. The inclusion criteria were: 1) ≥18 years of 
age, 2) CYP2C9 and VKORC1 genotype information available, 3) a diagnosis of 
a cardiovascular disease, 4) at least one warfarin purchase, 5) regular INR tests. 
Eligible individuals were divided into two warfarin sensitivity groups; normal respon-
ders, and sensitive and highly sensitive responders based on their VKORC1 and 
CYP2C9 genotypes. The incidences of clinical events were compared between the 
groups using Cox regression models.
Results: The cohort consisted of 2508 participants (45% women, mean age of 69 years), 
of whom 65% were categorized as normal responders and 35% sensitive or highly 
sensitive responders. Compared to normal responders, sensitive and highly sensitive 
responders had fewer INR tests below 2 (median: 33.3% vs 43.8%, 95% CI: −13.3%, 
−10.0%) and more above 3 (median: 18.2% vs 6.7%, 95% Cl: 8.3%, 10.8%). The 
incidence (per 100 patient-years) of bleeding outcomes was 5.4 for normal responders 
and 5.6 for the sensitive and highly sensitive responder group (HR=1.03, 95% CI: 0.74, 
1.44). The incidence of thromboembolic outcomes was 4.9 and 7.8, respectively 
(HR=1.48, 95% CI: 1.08, 2.03).
Conclusion: In a real-world setting, genetically sensitive and highly sensitive responders to 
warfarin had more high INR tests and required a lower daily dose of warfarin than normal 
responders. However, the risk for bleeding events was not increased in sensitive and highly 
sensitive responders. Interestingly, the risk of thromboembolic outcomes was lower in 
normal responders compared to the sensitive and highly sensitive responders.
Trial Registration: NCT04001166.
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Introduction
For decades warfarin has been a commonly used oral anticoagulant for the treat-
ment and prevention of thromboembolic events.1,2 Although efficacious, warfarin 
treatment is challenged by a narrow therapeutic range and high inter-individual 
variation in treatment response which increases the risk of treatment complications. 
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Warfarin is a leading cause of severe adverse drug reac-
tions and is responsible for up to one-third of adverse drug 
reaction-related emergency hospitalizations and 
fatalities.3–5
Approximately 50–60% of the inter-individual varia-
bility in the warfarin dose requirement is explained by 
genetic factors, particularly with variants in CYP2C9 and 
VKORC1.6–8 Individuals carrying decreased function 
alleles of CYP2C9 (eg, CYP2C9*2 and CYP2C9*3) have 
a reduced ability to metabolize warfarin, and those carry-
ing decreased function variants of VKORC1 are more 
sensitive to warfarin.6 Thus, they require lower warfarin 
doses to achieve therapeutic anticoagulation measured as 
an international normalized ratio of the prothrombin time 
(INR) in the range of 2–3.10 Individuals with these 
variant alleles are more likely to experience over- 
anticoagulation which might increase the risk for bleeding 
complications.11–13
A number of pharmacogenetic studies have assessed 
the effect of genotype-guided warfarin dosing, however, 
the evidence on its benefits remains contradictory.6,14–18 
Studies conducted are criticized for their small sample 
sizes and limited follow-up times, and for the use of 
surrogate end-points (ie, anticoagulation related para-
meters) rather than clinical events such as bleeding or 
thrombosis.19–21 Few studies have investigated the impact 
of the variant alleles on the incidence of clinical events, 
and most of them have been unpowered to show signifi-
cant differences. It has been shown that the incidence of 
hemorrhagic events is higher among genetically sensitive 
individuals with the risk for major hemorrhages increasing 
up to 2–5 fold.12,13,20,22,23 However, not all the studies 
have confirmed these associations.24–26 Moreover, it 
seems that the risk of minor bleeding events is not 
increased in variant allele carriers.23,27 The association 
between genotype and the risk of clinical events remains 
therefore unclear.
The large genome data resources of rapidly evolving 
biobanks linked with clinical data provide opportunities 
for pharmacogenetic research. Although causal inference 
is limited with the use of such resources, they provide 
a unique possibility to overcome some methodological 
challenges including insufficient sample sizes and the use 
of clinical outcome events. The aim of the current study 
was to assess the association between VKORC1 and 
CYP2C9 variants and the incidence of adverse drug reac-
tions in warfarin-treated patients in a real-world setting by 
using a register-linkage design with multiple Finnish bio-
banks and national health registries.
Materials and Methods
Study Design and Data Sources
This was a register-based cohort study (PreMed study) 
linking data from multiple Finnish biobanks and national 
health registries to investigate pharmacogenetics of 
antithrombotic drugs. Three biobanks (THL Biobank, 
Auria Biobank, Helsinki Biobank) first identified indivi-
duals genotyped in biobank studies for the selected 
genetic variants and with an eligible disease diagnosis 
(see Participants). These data together with the patients’ 
demographic data were then linked with individual’s 
medication purchases retrieved from the drug reimburse-
ment registry maintained by the Social Insurance 
Institution of Finland (Kela) to form the original 
PreMed cohort. The registry contains complete informa-
tion on all reimbursed drugs dispensed from Finnish 
pharmacies with the following information: the date of 
purchase, identification code (ATC code) of the medica-
tion and the purchased amount in milligrams and in 
defined daily doses (DDD). The cohort data were further 
linked to laboratory data from the registries of hospital 
districts and municipalities, and to health care encounter 
data that included diagnosis codes of outpatient visits and 
inpatient care using nationwide registers, the Care 
Register for Health Care and the Register of Primary 
Health Care Visits, both maintained by the Finnish 
Institute for Health and Welfare. The two registers contain 
data from all specialized and primary care episodes, 
respectively. The data were retrieved for the period of 
January 1st 2007-June 30th 2018, and the participants 
were followed until December 31st 2018. Data linking 
was done using the personal identity code assigned to 
every individual residing in Finland.
Participants
Individuals fulfilling the following inclusion criteria were 
included in the study: 1) ≥18 years of age at the first date 
of warfarin purchase, 2) CYP2C9 (*2 and *3 alleles; 
rs1799853 and rs1057910) and VKORC1 g.3588G>A 
(rs9923231) genotype information available in the bio-
bank, 3) a diagnosis of a cardiovascular disease 
(Supplementary material, Table S1), 4) at least one war-
farin purchase between January 1st 2007 and June 30th 
2018, 5) at least three INR test results. Individuals who 
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had made warfarin purchases between January 1st 2005 
and December 31st 2006 were excluded to ensure 
a washout period of two years.
Genotyping
Genotyping of the participants had been carried out in the 
framework of the on-going FinnGen project28 and past 
research projects of the Finnish Institute for Health and 
Welfare.29,30 The observed genotype frequencies were 
similar to those previously observed in the European popu-
lation, and the three variants were in Hardy–Weinberg 
equilibrium (Unpublished data). On the basis of the 
VKORC1 and CYP2C9 genotypes, patients were divided 
into three warfarin responder type groups; normal 
responders, sensitive responders, and highly sensitive 
responders.12
Warfarin Exposure
Warfarin exposure was defined as a period of a patient’s 
continuous warfarin purchases and INR tests. We first 
identified the date of the first warfarin purchase for each 
participant and set this as an initial start date for warfarin 
exposure. Then, INR data of each patient were analysed. If 
there were INR test results taken up to 30 days before the 
first warfarin purchase, the start date of warfarin exposure 
was corrected with the first date of these INR measure-
ments. Warfarin exposure between consecutive purchases 
was deemed continuous until the earliest of the follow-
ing: 1) the time difference between two INR test results 
was more than 60 days, 2) the time difference between two 
consecutive warfarin purchases was more than 500 days 
and all the purchased drugs had been consumed (based on 
the DDD information), 3) a direct oral anticoagulant 
(DOAC) or a heparin product was purchased 
(Supplementary material, Table S1), 4) the study follow- 
up ended (December 31st 2018).
Variables
Bleeding Events
The primary outcome was the occurrence of a bleeding 
event that occurred during warfarin exposure and was 
associated with one of the defined diagnosis codes 
(Supplementary material, Table S1). Recurrent bleeding 
events, referring to cases where the patient was diagnosed 
with a bleeding event before warfarin exposure and again 
during the exposure, were defined as outcomes, only if 
they were combined with a reduction in hemoglobin levels 
of 20g/dl, or greater. The same hemoglobin reduction 
degree was used for identifying major bleeding events. 
For all clinical outcome events, the participants were fol-
lowed from the first day of the warfarin exposure to the 
occurrence of the outcome event, or to the last date of 
exposure, whichever came first. In addition, only the first 
event occurring after the exposure and the corresponding 
follow-up was analyzed.
Thromboembolic Events
Clinical events occurring during the exposure and asso-
ciated with one of the defined diagnosis codes 
(Supplementary material, Table S1) were defined as 
thromboembolic outcomes. If a thromboembolic event 
with the identical ICD-10 code had occurred before the 
warfarin exposure, the subsequent thromboembolic event 
was deemed as an outcome only if combined with 
a hospital admission. Moreover, we used a blanking period 
of seven days indicating that the recurrent thromboembolic 
events occurring within seven days from the beginning of 
the exposure were excluded to ensure that the event was 
actually a new event, and not incorrectly interpreted as an 
outcome due to a delayed diagnosis registration.
Bleeding-related Hospitalizations
Hospital admissions (admission date, discharge date and 
related ICD-10 diagnosis code) were extracted from the 
Care Register for Health Care. All bleeding-related hospi-
talizations in specialized care occurring during the war-
farin exposure were included in the analyses.
INR Data
INR tests taken during the exposure time were extracted 
from the laboratory data and analyzed in detail to investi-
gate the anticoagulation effect. Restricting the INR data to 
the first 90 days, we calculated the following parameters: 
the number of INR tests, the time taken to reach the 
therapeutic range in days, the time in the therapeutic 
range (TTR) with interpolation according to the 
Rosendaal method,31 and the occurrence of below- and 
above-range INR levels (defined as INR < 2.0 and INR 
> 3.0). The desired therapeutic range for INR is between 2 
and 3 for most indications.10 The minimum number of 
INR test results per patient was three, otherwise the para-
meters were defined as missing values.
Drug Dosage
Average daily doses were calculated by dividing the total 
purchased amount of warfarin by the length of the expo-
sure period.
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Covariates
Information on sex and age was obtained via biobanks. 
The indication for warfarin use was identified on the basis 
of ICD-10 codes using the inclusion diagnosis that 
occurred closest before the warfarin initiation. Kidney 
function was investigated from laboratory data by apply-
ing the glomerular filtration rate (GFR).32
Significant interaction drugs (Supplementary material, 
Table S1) were identified based on class C and class 
D clinical significance using the inxbase drug–drug inter-
action database (https://www.medbase.fi/en/professionals/ 
inxbase). The patient was considered exposed to an inter-
acting drug if the drug was purchased at least once during 
warfarin exposure. The interacting drugs were categorized 
in two groups: drugs that increase the risk of bleeding 
events, and drugs that increase the risk for thromboem-
bolic events. Acetylsalicylic acid (ASA) was included in 
the list of bleeding risk-increasing drugs. The information 
on ASA use was obtained from medical records as ASA is 
an over-the-counter drug and thus those purchases are not 
included in the drug reimbursement registry.
Statistical Analyses
The initial inquiries in the biobanks indicated that 2678 
patients with genotype data could be recruited from the 
three biobanks. Assuming a risk of bleeding complications 
of 5%33 and the prevalence of CYP2C9 variant allele 
carriers of 35%,34 setting an alpha level of 0.05 and the 
power of 0.9, the estimated number of participants enabled 
us to detect an increase in the bleeding risk from 5% 
to 9%.
Baseline characteristics were presented for all study 
participants and across the three responder type groups: 
normal responders, sensitive responders and highly sensi-
tive responders. Similarly, the INR-related parameters 
were calculated across the responder type groups. We 
used nonparametric confidence intervals and estimators 
for the difference in the location parameters to assess the 
differences in the INR parameters. To investigate the 
number of patients who achieved therapeutic range, risk 
ratio (RR) and its 95% confidence interval (CI) were 
calculated.
The occurrence of outcome events was presented in 
terms of the incidence rates (per 100 patient years) for 
each responder type group. We used Cox proportional 
hazards regression models to investigate the associations 
between the responder type group and the occurrence of 
outcome events and bleeding-related hospitalizations. The 
follow-up time was restricted to 730 days in the main 
analyses. Both crude and adjusted results on hazard ratios 
(HR) and the 95% CIs were computed. The adjusted 
analyses included sex, age at the beginning of warfarin 
exposure, a diagnosis of cancer (during the warfarin expo-
sure or up to 2 years before the warfarin use), and the 
indication for warfarin use as potential confounders. In 
addition, the adjusted models for bleeding-related out-
comes included the use of bleeding risk-increasing drugs 
as a covariate, and, correspondingly, the thromboembolic- 
related outcomes included the use of thromboembolic risk- 
increasing drugs as a covariate.
We also performed three sensitivity analyses. First, we 
analyzed the occurrences of outcome events using the 
whole follow-up time instead of restricting it to 730 
days, and then further decreasing the follow-up to 90 
days. Secondly, we excluded the recurrent events from 
the analyses to include first-time diagnoses only. In the 
third analysis, an INR value of 3 or higher was required to 
coexist together with a bleeding event.
All analyses were conducted in R Studio version 
1.1.456 using R version 3.5.1 (2018–07-02).
Ethical Aspects
This study was conducted in accordance with the 
Declaration of Helsinki. The study was approved by the 
ethics committee of the Hospital District of Helsinki and 
Uusimaa (HUS/513/2019), and by all involved register 
controllers. After the data linkage in the biobanks, all the 
data were pseudonymized. The informed consent of the 
patients was obtained through the biobanks as defined in 
the Finnish Biobank Act 2013 (688/2012).35 The study 
was registered in the clinicaltrials.gov (NCT04001166).
Results
The original PreMed cohort consisted of 7005 patients. Of 
those, 36% (n=2508) fulfilled the eligibility criteria for the 
current study by having made at least one warfarin pur-
chase and having at least three INR test results (Figure 1).
Table 1 shows the characteristics of the study partici-
pants. Of the 2508 participants, 1133 (45.2%) were women 
and the mean age was 68.8 years. Based on the different 
variant alleles of the 2508 patients, 1627 (65%) were 
categorized as normal responders, 802 (32%) as sensitive 
responders, and 79 (3%) as highly sensitive responders. 
The most common inclusion diagnoses were atrial fibrilla-
tion and vascular disease (coronary artery or peripheric 
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artery disease). The sociodemographic characteristics and 
inclusion diagnoses did not differ across the responder 
type groups. A cancer was diagnosed more frequently in 
normal and sensitive responders than in highly sensitive 
responders. The exposure time was longer in normal 
responders than in sensitive and highly sensitive respon-
ders (372, 333 and 254 days, respectively). Moreover, the 
percentage of patients who changed from warfarin to 
DOACs differed between the groups with a decreasing 
trend toward highly sensitive responders (6.8%, 4.6% 
and 1.3%). There were no differences in the use of inter-
acting drugs between the genotype groups. The numbers 
(%) of ASA users were 269 (17%), 122 (15%), 13 (17%) 
for normal responders, sensitive responders, and highly 
sensitive responders. The mean daily dose of warfarin 
was lower among highly sensitive responders than in sen-
sitive and normal responders (2.6 mg/d vs 4.0 mg/d vs and 
5.5 mg/d, respectively).
Table 2 shows the INR parameters for the responder 
type groups during the first 90 days. The median num-
ber of INR tests was 12. The median percentage of the 
time in the therapeutic range and the time to reach the 
therapeutic range did not differ between the groups. 
Compared to normal responders, the sensitive and 
highly sensitive responders had fewer INR test results 
below 2 (33.3% vs 43.8%, 95% CI for median differ-
ence: −13.3%, −10.0%) and more above 3 (18.2% vs 
6.7%, 95% CI for median difference: 8.3%, 10.8%) 
during the first 90 days on warfarin.
During the median follow-up of 318 days, 149 bleed-
ing events occurred, resulting in 5.5 events per 100 
patient-years (Table 3). There were 97 and 52 bleeding 
events in the normal responder and sensitive responder 
groups, respectively. No events occurred in the highly 
sensitive group. Therefore, all subsequent outcome event 
analyses were performed by combining the sensitive and 
highly sensitive groups. The risk of bleeding events did 
not differ between the two responder type groups 
(HR=1.03, 95% CI: 0.74, 1.44), (Table 3 and Figure 
2). There was no difference in the bleeding-related hos-
pitalizations (HR=0.89, 95% CI: 0.51, 1.55). However, 
the incidence of thromboembolic events was higher in 
the sensitive and highly sensitive group with 4.9 and 7.8 
events per 100 patient-years in the normal, and sensitive 
and highly sensitive responder groups, respectively. 
Compared to normal responders, the risk was 1.48-fold 
for the sensitive and highly sensitive group (95% CI: 
1.08, 2.03) (Figure 3). Adjusting for potential confoun-
ders decreased the risk estimate for thromboembolic 
events to 1.37 (95% CI: 1.00, 1.88). The variant- 
specific HRs for bleeding events are presented in the 
Supplementary material (Table S2); the risk for bleeding 
events was increased in individuals who were homozy-
gous for CYP2C9*2 compared to non-carriers of the 
Figure 1 Participant recruitment and eligibility. 
Abbreviation: INR, international normalized ratio.
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allele (HR=3.35, 95% CI: 1.24, 9.09). There were no 
significant differences in the bleeding risk in relation to 
the VKORC1 or CYP2C9*3 allele carrier status 
(CYP2C9*3: HR=0.74, 95% CI: 0.42, 1.27; VKORC1: 
GG vs AG HR=0.87, 95% CI: 0.61, 1.23; GG vs AA 
HR=0.88 95% CI: 0.53, 1.46).
The sensitivity analyses showed that changing the 
length of the follow-up time either by analyzing the 
whole follow-up or by restricting it to the first 90 days 
did not alter the estimates (Table 4). Excluding recurrent 
thromboembolic events from the analyses strengthened 
the association between the genotype groups and the risk 
of thromboembolic events by increasing the HR to 1.82 
(95% CI: 1.23, 2.71) in sensitive and highly sensitive 
responders. There were no recurrent bleeding events 
and thus those analyses were not repeated.









Number of participants 2508 1627 802 79
Sex, female, n (%) 1133 (45.2) 726 (44.6) 374 (46.6) 33 (41.8)
Age, years, mean (sd) 68.8 (10.4) 68.8 (10.4) 68.9 (10.5) 67.9 (9.1)
Indication for warfarin use
Atrial fibrillation, n (%) 1596 (63.6) 1028 (63.2) 511 (63.7) 57 (72.1)
Vascular disease, n (%) 352 (14.0) 235 (14.4) 107 (13.4) 10 (12.7)
Pulmonary embolism, n (%) 199 (8.0) 122 (7.5) 74 (9.2) 3 (3.8)
Stroke or atherosclerosis in cerebral 
arteries, n (%)
127 (5.1) 78 (4.8) 45 (5.6) 4 (5.1)
Phlebitis or thrombophlebitis, n (%) 181 (7.2) 124 (7.6) 52 (6.5) 5 (6.3)
Other venous thrombosis, n (%) 53 (2.1) 40 (2.5) 13 (1.6) 0
VKORC1
GG, n (%) 961 (38.3)
AG, n (%) 1183 (47.2)
AA, n (%) 364 (14.5)
CYP2C9
CYP2C9*1/*1, n (%) 1690 (67.4)
CYP2C9*1/*2, n (%) 473 (18.9)
CYP2C9*1/*3, n (%) 274 (10.9)
CYP2C9*2/*2, n (%) 24 (1.0)
CYP2C9*2/*3, n (%) 36 (1.4)
CYP2C9*3/*3, n (%) 11 (0.4)
Exposure time, days, median [IQR] 352 [123–1200] 372 [137–1256] 333 [116–1110] 254 [96–843]
Changed to DOAC, n (%) 148 (5.9) 110 (6.8) 37 (4.6) 1 (1.3)
Changed to heparin products, n (%) 413 (16.5) 277 (17.0) 127 (15.8) 9 (11.4)
Interacting drugs
Increasing risk of bleeding events, n (%) 1833 (73.1) 1195 (73.5) 581 (72.4) 57 (72.2)
Increasing risk of thromboembolic events, 
n (%)
16 (0.6) 11 (0.7) 5 (0.6) 0






77.6 (18.7)  
missing=15
Diagnosis of cancer a, n (%) 492 (19.6) 333 (20.5) 150 (18.7) 9 (11.4)
Genotyped in the clinic b, n (%) 7 (0.3) 5 (0.3) 1 (0.1) 1 (1.3)
Daily dose, mg/d, median [IQR] 5.0 [3.7–6.7] 5.5 [4.3–7.1] 4.0 [3.0–5.3] 2.6 [1.9–5.0]
Notes: aCancer diagnosed during the warfarin exposure or up to 2 years before the warfarin initiation; bA pharmacogenetic test for CYP2C9 and VKORC1 performed to 
guide warfarin dosing. 
Abbreviations: DOAC, direct oral anticoagulant; GFR, glomerular filtration rate; IQR, interquartile range; SD, standard deviation.
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Discussion
The results of this study showed that in a real-world 
setting, the genetically sensitive and highly sensitive 
responders to warfarin did not have an increased risk of 
bleeding complications when compared to normal respon-
ders. Nevertheless, they had more out-of-range INR test 
results and required a lower daily dose of warfarin than 
normal responders. In addition, we found that sensitive 
and highly sensitive responders to warfarin had a higher 
risk of thromboembolic events. This was one of the largest 
studies investigating the impact of genetic variants on the 












































































































































































































































































































































































































































































































































































































Figure 2 Cumulative incidence of bleeding events.
Figure 3 Cumulative incidence of thromboembolic events.
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We found that among all study participants the median 
percentage of time in the therapeutic range (TTR) was 
58% during the first 90 days, and the TTR was not depen-
dent on the genotype. It has been suggested that sufficient 
anticoagulation is achieved with a minimum threshold for 
a TTR ranging from 58%-65%, whereas patients with 
a TTR ≤ 40% have shown a notable risk of clinical 
complications.33,36 The outcome was optimal in those 
patients with a TTR higher than 80%.33 This indicates 
that the majority of participants in this study achieved 
sufficient anticoagulation despite their genetic susceptibil-
ity to over-anticoagulation, which might further relate to 
our neutral findings on the bleeding risk. The TTR level 
seems to have been in line with other registry-based 
studies36 although it was slightly lower than in the 
Finnish nationwide FinWAF-study.33 However, the mean 
TTR in the FinWAF, 62% was achieved with the mean 
follow-up time of 3.2 years, while in the present study the 
TTR was analyzed for only the first 90 days on warfarin 
including the high variation period.
Although sensitive and highly sensitive responders had 
more INR test results above 3, the risk of bleeding com-
plications, regardless of the follow-up time used in the 
analyses, was not higher when compared to normal 
responders. Neither was there a difference in bleeding- 
related hospitalizations. In line with our findings, several 
studies have reported an increased anticoagulation effect 
and lower dose requirements to be associated with these 
genetic alleles.6,12,20,37–39 Some studies have shown an 
increased bleeding risk with CYP2C9 and VKORC1 allele 
variants,11–13,39 while in most studies as well as in the 
meta-analysis of Jorgensen et al the allele variants have 
not been associated with increased risk of bleeding.24,40–42 
On the other hand, in the very large Phase III trials, 
HOKUSAI-VTE and ENGAGE AF-TIMI 48 (together 
more than 8000 patients on warfarin), genetic polymorph-
isms in CYP2C9 and VKORC1 affected the safety of 
warfarin.11,12 However, this finding was underscored in 
patients with highly sensitive genotype, whilst the number 
of those was only modest in our study. Park et al suggested 
that clinical events are more associated with patients’ 
characteristics and clinical practices than with genetic 
factors.42 Our findings support this interpretation; sensitive 
and highly sensitive responders had lower daily doses of 
warfarin indicating that the over-anticoagulation was 
detected and corrected with dose adjustment. Another 
factor contributing to the neutral bleeding risk could be 
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risk is frequently seen concerning major bleeding events 
only. In fact, Tomek et al showed that minor bleeding 
events alone were not associated with genotype.27
The sensitivity analyses showed that the incidence of 
bleeding events did not differ between the responder type 
groups regardless of whether we investigated the risk 
either during the first 90 days or over the whole follow- 
up of approximately 318 days. Some studies have sug-
gested that the bleeding risk is higher during warfarin 
initiation in particular.12,20,41
The increased risk of thromboembolic events among 
sensitive and highly sensitive responders remains unclear, 
and contradictory to our INR test result findings. Compared 
to normal responders, sensitive and highly sensitive respon-
ders had nearly a 1.5-fold risk of suffering thromboembolic 
events, which further increased almost 2-fold when recurrent 
thromboembolic events were excluded despite that these 
individuals had significantly fewer INR test results below 
2. However, the INR test results showed that sensitive 
responders and highly sensitive responders, in particular, 
had more INR tests above 3. Individuals with high INR 
values are sometimes advised to pause warfarin treatment 
or adjust warfarin dose, which might actually expose them to 
thromboembolic outcomes. Moreover, a lower percentage of 
highly sensitive responders reached the therapeutic range 
during the first 90 days, and they reached it seven days 
later on average. It seems that highly sensitive responders 
had greater challenges finding the optimal warfarin dose.
Limitations
The findings of this study should be interpreted in the 
light of the following limitations. First, although data 
obtained from nationwide registries have been validated 
and have been shown to be of good quality,43,44 in this 
study the use of registry data posed limitations to inves-
tigating warfarin exposure and the identification of out-
comes. Estimating warfarin exposure through drug 
purchase data did not reveal whether and when the 
warfarin was actually used. In an attempt to increase 
the likelihood of true warfarin exposure, we required 
that the patient adhered to regular INR tests according 
to national guidelines in Finland.We consider the use of 
INR data together with warfarin purchases as a strength 
of this study which is not frequently used in other 
register-based studies. In terms of identifying throm-
boembolic outcomes, we cannot rule out the possibility 
of misclassification of the patients’ prior events as an 
outcome event. To minimize such bias, events with the 
same diagnosis codes were included only if they 
occurred at least seven days after the first diagnosis 
and were combined with a hospital admission. In addi-
tion, we conducted sensitivity analyses in which we 
excluded all recurrent events, and those results consis-
tently showed a risk-increasing effect. For bleeding out-
comes, bleeding-related hospital admissions were 
separately analyzed, and those results also indicated 
a small risk of misclassification.
Second, despite the study including 2508 partici-
pants, the sample size was not sufficient to investigate 
differences across the three genotype groups. No bleed-
ing events occurred among highly sensitive responders, 
and therefore, we needed to combine sensitive and 
highly sensitive responder groups. Interestingly, the 
results of the INR data indicated that the highly sensi-
tive responders faced most challenges with anticoagula-
tion suggesting an increased risk of bleeding events. 
Moreover, although the sample size remained slightly 
lower than we anticipated, this study found a significant 
association between CYP2C9*2 and a bleeding risk (HR 
of 3.35), which was used as a basis for sample size 
calculations, and which was also in line with earlier 
reported studies.20,23,46
Third, we had no data on mortality. Thus, we may 
have ignored cases of fatal bleedings where the patient 
died without being admitted to hospital. However, we 
did not expect death rates to differ between the geno-
types as the variants investigated in this study are fre-
quently related to non-fatal clinical outcomes.
Fourth, there may still be residual bias present in the 
study as we were able to control only a few possible 
confounding factors. We did not have data on behavioral 
factors such as smoking, alcohol use and dietary factors, 
vitamin K intake in particular, that influence anticoagu-
lation and hence they could explain the results. In addi-
tion, information on the body size affecting dose 
requirements was not available.47
Conclusions
In a real-world setting, the genetically sensitive and 
highly sensitive responders to warfarin had more INR 
test results above 3 and required a lower daily dose of 
warfarin than normal responders. However, the risk of 
bleeding events was not significantly increased for the 
sensitive and highly sensitive responders. On the con-
trary, the risk of thromboembolic outcomes was lower 
for the normal responders. Our results suggest that 
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genotype-guided warfarin dosing may have limited 
advantages in preventing bleeding complications but 
might help to identify patients who are at a high risk 
of thromboembolic events.
Abbreviations
ASA, acetylsalicylic acid; CI, confidence interval, DDD, 
defined daily doses; DOAC, direct oral anticoagulant; 
GFR, glomerular filtration rate; HR, hazard ratio; INR, 
international normalized ratio; IQR, interquartile 
range; mg, milligram; RR risk ratio; SD, standard devia-
tion; TTR, time in therapeutic range.
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